Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8949212 | Journal of Geriatric Oncology | 2018 | 8 Pages |
Abstract
Checkpoint inhibitors offer an exciting new option for treatment of a wide variety of cancers. By binding to surface receptors or their associated ligands on T cells, this class of drugs enhances immune activation and response to cancer cells. In available studies, the drugs are well tolerated, although toxicity involving skin, gastrointestinal tract, liver, lungs, and endocrine organs has been observed. Unfortunately, few studies to date have included patients older than 70â¯years of age. Since aging has been linked to changes in immune function, there are theoretical concerns that this patient population might experience a different profile of adverse events. This article reviews the tolerability of checkpoint inhibitors in older patients with cancer in clinical practice.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Omar Alkharabsheh, Paul Kannarkatt, Joseph Kannarkatt, Lilit Karapetyan, Heather S. Laird-Fick, Anas Al-Janadi,